Dr. Saver
We can do better in stroke prevention by using them (Amplatzer PFO) in the appropriate patient.”
About the Amplatzer™ PFO Occluder
A pioneering device known around the world
Abbott created the PFO occlusion category, and the Amplatzer™ PFO Occluder has sustained leadership over decades of use and was the first device supported by positive trial results.
Often imitated, never matched
Industry-leading device.¹
Developed specifically for the treatment of PFO closure.
Device design
- Percutaneous, transcatheter closure
- Self-expanding, double-disc design
- Nitinol wire mesh with polyester fabric/thread
- Recapturable and repositionable
- FDA approval in 2016; CE Mark in 1998
Learn more about the PFO closure procedure
Discover how the Amplatzer™ PFO Occluder is implanted through a minimally invasive, same-day, out-patient procedure.
About the procedure† Effective closure
*On commonly used sizes (25mm and 35mm devices)- Internal data. Data on-file at Abbott.
- Heinrich P. Mattle, Stefan Evers, David Hildick-Smith, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial, European Heart Journal, Volume 37, Issue 26, 7 July 2016, Pages 2029–2036.